Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-69Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-08-14 / Cancer Cell 2017 08;32(2):253-267.e5Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial Carcinoma /von 2017-06-07 / Biomed Res Int 2017;2017:5618174Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2017-06-01 / Neuro-oncology 2017 06;19(6):796-807Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2017-05-24 / Neurol. Med. Chir. (Tokyo) 2017 Jul;57(7):321-330Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
/in Brain Tumors in Children, Checkpoint-Inhibitors, Glioblastoma, International Publications /von 2017-04-12 / Onco Targets Ther 2017;10:2097-2106Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
/in Checkpoint-Inhibitors, Glioblastoma, International Publications /von 2017-04-01 / Cancer Control 2017 Apr;24(2):180-186Targeting immune checkpoints in malignant glioma
/in Checkpoint-Inhibitors, Glioblastoma, International Publications /von 2017-01-24 / Oncotarget 2017 Jan;8(4):7157-7174
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de